An editorial is presented in which the author discusses ventilator-associated pneumonia (VAP) as the common and morbid complication of mechanical ventilation. It discusses technical innovations to reduce biofilm accumulation and passage of secretions. It also discusses improvements in patient-centered outcomes in "real-world" populations.